Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study.
Summary
This international study aimed to identify genetic prognostic biomarkers in a specific subgroup of intermediate-risk neuroblastoma patients, over 18 months old, without MYCN amplification, with localized unresectable or stage 3 tumors, and unfavorable histology, who experience poorer outcomes. Researchers analyzed chromosomal copy number alterations, next-generation DNA sequencing, telomere maintenance mechanisms, and gene expression. The findings revealed that oncogene amplifications, p53 pathway alterations, and typical segmental chromosomal aberrations (tSCAs) are independent prognostic markers associated with significantly reduced event-free and overall survival. These discoveries suggest that these patients might benefit from intensified or alternative treatments.
Analysis
🔴 CLINICAL: This large-scale, international study identifies crucial prognostic biomarkers for a specific subpopulation of intermediate-risk neuroblastoma patients. Oncogene amplifications (CDK4, MDM2, TERT, MYC), p53 pathway alterations, and typical segmental chromosomal aberrations (tSCAs) are independent predictors of poor prognosis, associated with significantly reduced event-free and overall survival. For instance, patients with oncogene amplification had a 5-year event-free survival of 0%. These findings, from an observational study, justify considering intensified or alternative treatments for these patients, potentially within phase II/III clinical trials. The clinical impact could be seen in the medium term (3-5 years) to guide therapeutic decisions. 🟢 BIOMOL: The research discovered several genetic biomarkers with significant prognostic impact. The study employed a combination of techniques, including chromosomal copy number analysis, next-generation DNA sequencing (NGS) for most cases, and analysis of telomere maintenance mechanisms and gene expression for a subset. These technologies enabled the identification of specific oncogene amplifications (CDK4, MDM2, TERT, MYC), p53 pathway alterations, and segmental chromosomal aberrations. The detection of these alterations in tumor samples (likely FFPE) has analytical validity demonstrated by correlation with survival. These discoveries have a direct translational impact, suggesting that these markers could be integrated into clinical tests to stratify patients and guide therapies.